Warning: fopen(/home/virtual/epih/journal/upload/ip_log/ip_log_2024-10.txt): failed to open stream: Permission denied in /home/virtual/lib/view_data.php on line 95 Warning: fwrite() expects parameter 1 to be resource, boolean given in /home/virtual/lib/view_data.php on line 96
Ramathibodi School of Nursing, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
© 2024, Korean Society of Epidemiology
This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Parameters | Inclusion criteria |
---|---|
P: Participants | Worldwide community-dwelling older adults aged 60 yr or above with sarcopenia |
I: Intervention | Underwent protein supplementation combined with resistance exercise |
C: Comparison intervention | Usual care |
Q: Outcome measures | Components of sarcopenia (muscle mass, muscle strength, physical performance) |
Study | Diagnosis of sarcopenia | Participants (n) |
Country study | Intervention |
Duration (wk) | Component of sarcopenia | |||
---|---|---|---|---|---|---|---|---|---|
Age (yr) | PS and RE | CG | RE | PS | |||||
Shahar et al., 2013 [29] | BIA: SM cut-off points <0.75 kg/m2 for male and 6.75 kg/m2 for female | 65 older adults with sarcopenia, age ≥60 | 15 | 16 | Malaysia | RE program, 2 session/wk, 60 min for each session (elastic band) | One time/day | 12 | Improved |
- Soy protein drink 20 g/day and 40 g/day, in a powder form was given to male and female subjects, respectively | • Muscle mass | ||||||||
Maltais et al., 2016 [33] | MMI | 26 older male with sarcopenia, age ≥60 | 8 | 10 | Canada | RE program, 3 session/wk, 1-hr for each session (free weightlifting and resistance equipment for leg press, bench press, leg extension, and shoulder press, sit-ups, rowing extensions, biceps curls, and leg curls) | Suppl immediately after the exercise session | 16 | Improved |
1. EAA supp (12 g protein, 7 g of EAA) | • Muscle strength | ||||||||
2. Milk supp (13.53 g protein, 7 g of EAA) | |||||||||
Zhu et al., 2019 [34] | AWGS, 2014 | 113 older male with sarcopenia, age ≥65 | 36 | 37 | Hong Kong | RE program, 2 session/wk, 90 min for each session (chair-based RE exercises, aerobic exercises); One-home session weekly | 2 Sachets a day | 12 | Improved |
- Ensure NutriVigor daily from baseline to 12 wk (54.1 g powder; 8.61 g protein, 1.21 g BMD, 130 IU vitamin D and 0.29 g omega-3 fatty acid) | • Muscle strength | ||||||||
• Physical performance | |||||||||
Vikberg et al., 2019 [30] | EWGSOP, 2010 | 70 older adults with sarcopenia, age ≥70 | 32 | 34 | Sweden | RE program, 3 session/wk, 45 min for each session (body weight, suspension band) | One time/day | 10 | Improved |
- Week 1 to 7: milk 250 mL (21 g protein) | • Muscle mass | ||||||||
- Week 8 to 10: milk 250 mL (30 g protein) | • Maintaining functional strength | ||||||||
Chang et al., 2021 [32] | EWGSOP, 2010 | 57 older male with sarcopenia, age ≥65 | 29 | 28 | Taiwan | 2 session/wk | 1. 2 Sticks of daily branched-chain amino acids (BCAA-Amino Vital Pro®, Ajinomoto) (800 IU of cholecalciferol and 600 mg of calcium) | 12 | Improved |
1. A hospital-based program involving physical therapy and rehabilitation in hospital | • Muscle mass | ||||||||
2. Home-based exercise (Keiser Sports Health Equipment) | 2. 2 Tablets daily of calcium and vitamin D3 supplement (Caltrate, Pfizer, USA) for 12 wk (800 IU of cholecalciferol and 600 mg of calcium) | ||||||||
Li et al., 2021 [27] | AWGS, 2014 | 241 older adults, age ≥60 | 59 | 59 | China | Aerobic and RE program, 3 session/wk, 30 min for each session (dumbbells and sandbags) | 1. PRO powder 10 g, 3 times daily with meals | 12 | Improved |
2. EPA (300 mg), DHA (200 mg), and vitamin D3 (250 IU) 2 pills/time and 2 time/day | • Muscle mass | ||||||||
• Muscle strength | |||||||||
Wang et al., 2022 [31] | AWGS, 2019 | 201 older adults with sarcopenia, age ≥65 | 60 | 54 | China | The app evaluated the participant’s exercise status and recommended the amount of exercise, such as 40 to 60 min of moderate-to-high-intensity exercise (brisk walking and jogging) and resistance training (seated leg raises, static squat against a wall, dumbbell lifts, elastic bands, etc.) for 30 min, ≥3 day/wk | The app featured the ability to assess each participant’s diet and provide recommendations for adjustments, focusing on energy and protein intake, especially the high-quality protein, and give recommended recipes | 12 | Improved |
• Muscle mass | |||||||||
Mori et al., 2022 [28] | AWGS, 2014 | 81 older adults with sarcopenia, age ≥65 | 21 | 21 | Japan | RE program 2 session/wk, 40 min for each session | PRO supplement: 11.0 g of protein, and 2,300 mg of leucine per serving | 24 | Improved |
1. RT+PRO group ingested the protein supplement within 5 min after completion of the RT program | • Muscle mass | ||||||||
2. PRO groups ingested the PRO supplement 3 hr after lunch | • Muscle strength |
Study | JBI critical appraisal of the eligible |
|||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Q1 | Q2 | Q3 | Q4 | Q5 | Q6 | Q7 | Q8 | Q9 | Q10 | Q11 | Q12 | Q13 | Total score | |
Quasi-experimental study |
||||||||||||||
Shahar et al. [29] | Y | Y | Y | Y | Y | Y | Y | Y | Y | - | - | - | - | 9/9 |
Randomized controlled trials (RCTs) |
||||||||||||||
Maltais et al. [33] | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | 13/13 |
Zhu et al. [34] | Y | Y | Y | Y | N | N | N/A | Y | Y | Y | Y | Y | Y | 10/13 |
Vikberg et al. [30] | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | 13/13 |
Chang et al. [32] | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | 13/13 |
Li et al. [27] | Y | Y | Y | N/A | N | N | N/A | Y | Y | Y | Y | Y | Y | 9/13 |
Wang et al. [31] | Y | Y | Y | Y | N | N | Y | Y | Y | Y | Y | Y | Y | 11/13 |
Mori et al. [28] | Y | Y | Y | Y | N | N | N/A | Y | Y | Y | Y | Y | Y | 12/13 |
PS and RE, protein supplementation combined with resistance exercise; CG, control group; BIA, bioelectrical impedance analysis; SM, skeletal muscle; MMI, muscle mass index; EWGSOP, European Working Group on Sarcopenia in Older People; AWGS, Asian Working Group for Sarcopenia; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; EAA supp, essential amino acid; Milk supp, milk supplement; RT, resistance training; PRO, whey protein.
Y, yes; N, no; N/A, not applicable. Q1: Is it clear in the study what is the ‘cause’ and what is the ‘effect’ (i.e., there is no confusion about which variable comes first)?; Q2: Were the participants included in any comparisons similar?; Q3: Were the participants included in any comparisons receiving similar treatment/care, other than the exposure or intervention of interest?; Q4: Was there a control group?; Q5: Were there multiple measurements of the outcome both pre and post the intervention/exposure?; Q6: Was follow up complete and if not, were differences between groups in terms of their follow up adequately described and analyzed?; Q7: Were the outcomes of participants included in any comparisons measured in the same way?; Q8: Were outcomes measured in a reliable way?; Q9: Was appropriate statistical analysis used? Q1: Was true randomization used for assignment of participants to treatment groups?; Q2: Was allocation to treatment groups concealed?; Q3: Were treatment groups similar at the baseline?; Q4: Were participants blind to treatment assignment?; Q5: Were those delivering treatment blind to treatment assignment?; Q6: Were outcomes assessors blind to treatment assignment?; Q7: Were treatment groups treated identically other than the intervention of interest?; Q8: Was follow up complete and if not, were differences between groups in terms of their follow up adequately described and analyzed?; Q9: Were participants analyzed in the groups to which they were randomized?; Q10: Were outcomes measured in the same way for treatment groups?; Q11: Were outcomes measured in a reliable way?; Q12: Was appropriate statistical analysis used?; Q13: Was the trial design appropriate, and any deviations from the standard RCT design (individual randomization, parallel groups) accounted for in the conduct and analysis of the trial?